News at CenExel

Advancements in Vaccines: Bridging the Past and Future

    Advancements in Vaccines: Bridging the Past and Future - by Nelia Sanchez-Crespo, MD The history of vaccines is a testament to the incredible progress we've made in protecting humanity against infectious diseases. From the invention of the smallpox...

A link between seizure and stuttering disorders? A case report

CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the recent Cerevel Therapeutics study titled, Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial, published in The Lancet.

Join CenExel at CNS Summit 2021

Join CenExel at CNS Summit 2021

CenExel Clinical Research Network is excited to announce our presence at the upcoming CNS Summit 2021 in Boston, Massachusetts on November 7-11, 2021. The mission of the CNS Summit is to have a positive impact on the success of clinical development programs as an...

CenExel Clinical Research Acquires CITrials

Salt Lake City, Mar. 9, 2021 /PRNewswire/ — CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of CITrials, a southern California-based clinical research firm with three sites serving Los Angeles, Orange, and Riverside/San Bernardino counties....